Last reviewed · How we verify

Metronidazole Topical Gel

Riyadh Elm University · Phase 1 active Small molecule Quality 0/100

Metronidazole Topical Gel is a Small molecule drug developed by Riyadh Elm University. It is currently in Phase 1 development. Also known as: Roza 0.75% will be delivered locally in the periodontal pocket.

At a glance

Generic nameMetronidazole Topical Gel
Also known asRoza 0.75% will be delivered locally in the periodontal pocket
SponsorRiyadh Elm University
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metronidazole Topical Gel

What is Metronidazole Topical Gel?

Metronidazole Topical Gel is a Small molecule drug developed by Riyadh Elm University.

Who makes Metronidazole Topical Gel?

Metronidazole Topical Gel is developed by Riyadh Elm University (see full Riyadh Elm University pipeline at /company/riyadh-elm-university).

Is Metronidazole Topical Gel also known as anything else?

Metronidazole Topical Gel is also known as Roza 0.75% will be delivered locally in the periodontal pocket.

What development phase is Metronidazole Topical Gel in?

Metronidazole Topical Gel is in Phase 1.

Related